A phase 2a multicentric study of TAR-0520 gel in EGFR inhibitor-induced folliculitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516339-28-00

Acronym

TARIAN 007

Enrollment

Registered

2024-11-13

Start date

2025-02-10

Completion date

Unknown

Last updated

2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR inhibitor-induced folliculitis

Brief summary

Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events

Detailed description

Modified folliculitis CTCAE, Facial folliculitis severity score, Modified FACT-EGFRI-18 questionnaire

Interventions

DRUGTAR-0520 gel matching vehicle without active ingredients

DRUGTAR-0520 Gel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events	—

Secondary

Measure	Time frame
Modified folliculitis CTCAE, Facial folliculitis severity score, Modified FACT-EGFRI-18 questionnaire	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026